111, Inc. Deepens Partnership With Bayer Healthcare
111, Inc. (YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, announced the expansion of its existing partnership with Bayer Healthcare Co. Ltd. (“Bayer”).
111 and Bayer Healthcare first entered into a strategic partnership in September 2020, to collaborate on drug commercialization initiatives in China. Specifically, 111 and Bayer agreed to work towards the commercialization of innovative drugs and healthcare products for chronic disease management, as well as providing useful resources for patient education. Leveraging 111’s vast network of pharmacies and healthcare providers facilitates the expansion of Bayer’s presence in underserved markets in China, as well as enhances the leading drug maker’s channel management and patient outreach capabilities. The two companies also agreed to jointly develop a digital content portal that provides online pharmacist training, as well as interactive patient education, and other services. The goal of this platform is to allow patients, healthcare providers, and pharmaceutical companies to work together to create patient-centric healthcare management plans that focus on providing quality service, in a more convenient and less restrictive way for the patient.
Currently, 111 is the only e-commerce company in China to have secured a direct sourcing partnership with Bayer. The new agreement deepens this relationship, as 111 will also assist Bayer with commercialization through proprietary technology, including its SMART supply chain, big data, and cloud services. Expanding the partnership still further, 111 will cover an increased number of innovative drugs for Bayer, as the two companies will work together to achieve greater penetration in the wider online and offline markets. Also growing is the number of therapeutic areas that 111 covers for Bayer, which now will encompass diabetes, oncology, cardiovascular, cerebral and gynecology. Finally, the two parties will leverage 111’s e-hospital capabilities to construct a disease management platform to create a digital “healthcare + medicine” service model for patients including doctor-patient communication, disease course management, and online and offline DTP delivery of medicines.
111’s Co-Founder and Executive Chairman, Dr. YU Gang, commented, “We are very pleased with what Bayer and 111 have been able to accomplish together through our partnership, and look forward to our continuing to innovate together in the area of healthcare. By leveraging our respective strengths and expertise, the two companies will jointly explore more efficient healthcare delivery models, advancing the traditional healthcare system to the modern era of digital “healthcare + medicine” to provide people in China with high-quality products and convenient services, and to help build a “healthy China“.”
Ms. LUO Xiaojie, Senior Vice President at Bayer Pharmaceuticals, commented, “While Bayer and 111 have already developed a mutually cooperative relationship, in many ways this agreement marks a new beginning. It will better enable both parties to give full play to their unique advantages in the medical and pharmaceutical fields, and the innovative digital service model will create value for the pharmaceutical industry and benefit more Chinese patients.”